Corneal Verticillata After Dual Anti-Epidermal Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Receptor 2 Therapy (Vandetanib) for Anaplastic Astrocytoma
| Autor: | Howard A. Fine, Steven Yeh, Janine A. Smith |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
Astrocytoma Sodium Chloride Vandetanib Vascular endothelial growth inhibitor Drug Administration Schedule Corneal Diseases Ointments Corneal Opacity Cellulase Piperidines Internal medicine medicine Humans Growth factor receptor inhibitor Retrospective Studies Dose-Response Relationship Drug Brain Neoplasms business.industry Kinase insert domain receptor Middle Aged medicine.disease Vascular Endothelial Growth Factor Receptor-2 ErbB Receptors Epithelial basement membrane dystrophy Ophthalmology Vascular endothelial growth factor A Endocrinology Vascular endothelial growth factor C Quinazolines Cancer research Drug Therapy Combination Female Neoplasm Recurrence Local business Anaplastic astrocytoma medicine.drug |
| Zdroj: | Cornea. 28:699-702 |
| ISSN: | 0277-3740 |
| Popis: | To describe a patient with a history of epithelial basement membrane dystrophy who developed symptomatic corneal verticillata after vandetanib therapy for anaplastic astrocytoma.Retrospective interventional case report.A 48-year-old female patient with a history of anaplastic astrocytoma status post resection, external beam radiation, and chemotherapy presented with glare symptoms, decreased contrast sensitivity, and increased lacrimation after approximately 12 months of therapy with the anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor, vandetanib. Ophthalmic examination revealed diffuse corneal verticillata and fine subepithelial opacities. Schirmer 1 testing was normal bilaterally. Therapy with carboxymethylcellulose, 5% sodium chloride ointment, and a decrease in the dose of vandetanib led to an improvement in the patient's ophthalmic symptoms despite persistence of the corneal findings. The patient remained under surveillance for tumor recurrence.Vandetanib (ZD6474), a protein tyrosine kinase inhibitor with dual anti-EGFR and anti-vascular endothelial growth factor receptor 2 action, may have contributed to the formation of corneal verticillata in our patient. Inhibition of EGFR, which is involved with corneal epithelial cell migration and wound healing, may play a role in the pathogenesis underlying corneal vortex keratopathy and ocular surface conditions with significant epithelial turnover. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|